Therapeutic area
Respiratory
Last checked: Nov 19, 2026Source: Drugs@FDA, ClinicalTrials.govMethods & limitations
Approvals since 2023
6
Originals, plus breakthrough or accelerated new uses
Recruiting Phase 2
82
Industry-sponsored
Recruiting Phase 3
63
Industry-sponsored
Recruiting Phase 4 (post-approval)
7
Industry-sponsored
Recent approvals
- Exdensur (Depemokimab-Ulaa) · Glaxosmithkline LLC NovelDec 16, 2025
To treat severe asthma characterized by an eosinophilic phenotype as an Komziftiadd-on maintenance therapy
- Jascayd (Nerandomilast) · Boehringer Ingelheim NovelBreakthrough therapyPriority reviewOrphanOct 7, 2025
To treat idiopathic pulmonary fibrosis
- Brinsupri (Brensocatib) · Insmed INC NovelBreakthrough therapyPriority reviewAug 12, 2025
To treat non-cystic fibrosis bronchiectasis
- Alyftrek (Deutivacaftor, Tezacaftor, Vanzacaftor Calcium) · Vertex Pharms INC NovelPriority reviewOrphanDec 20, 2024
For the treatment of cystic fibrosis (CF) in patients 6 years of age and older
- Ohtuvayre (Ensifentrine) · Msd NovelJun 26, 2024
To treat chronic obstructive pulmonary disease
- Winrevair (Sotatercept-Csrk) · Merck Sharp Dohme NovelBreakthrough therapyPriority reviewOrphanMar 26, 2024
To treat pulmonary arterial hypertension
Recruiting trials by phase
Industry-sponsored drug and biologic trials.
Most approvals since then, by company
- GSK1
Drugs in development
Investigational drugs in Phase 2 and 3 trials for conditions in this area, most trials first.
- BrenipatideLY3537031Phase 313 trials
Eli Lilly · Alcohol Use Disorder, Irritable Bowel Syndrome, Depressive Disorder, Major
- PovorcitinibINCB054707, INCB54707Phase 312 trials
Incyte · Hidradenitis Suppurativa (HS), NonSegmental Vitiligo, Prurigo Nodularis
- CM512Phase 39 trials
Keymed Biosciences Co.Ltd · Chronic Rhinosinusitis With Nasal Polyposis, Chronic Spontaneous Urticaria (CSU), Asthma
- HSK44459Phase 39 trials
Haisco Pharmaceutical Group Co., Ltd. · Psoriasis, Idiopathic Pulmonary Fibrosis (IPF), Progressive Pulmonary Fibrosis
- ItepekimabREGN3500, SAR440340Phase 39 trials
Sanofi · Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps, Bronchiectasis
- LP-003SinglePhase 39 trials
Longbio Pharma · Allergic Asthma, Chronic Spontaneous Urticaria (CSU), Peanut Allergies
- LunsekimigSAR443765Phase 39 trials
Sanofi · Asthma, Chronic Obstructive Pulmonary Disease, Chronic Rhinosinusitis With Nasal Polyps
- GSK5784283Phase 38 trials
GSK · Pulmonary Disease, Chronic Obstructive, Asthma, Nasal Polyps
- PF-07275315tilrekimigPhase 38 trials
Pfizer · Atopic Dermatitis, Asthma, Moderate to Severe Chronic Obstructive Pulmonary Disease
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- MG-K10Humanized Monoclonal AntibodyPhase 36 trials
Shanghai Mabgeek Biotech.Co.Ltd · Dermatitis, Atopic, Chronic Urticaria, Idiopathic, Atopic Dermatitis
- SHR-1905Phase 36 trials
Guangdong Hengrui Pharmaceutical Co., Ltd · Asthma, Chronic Rhinosinusitis With Nasal Polyps, Moderate-to-severe Atopic Dermatitis
- TozorakimabMEDI3506Phase 36 trials
AstraZeneca · Chronic Obstructive Pulmonary Disease (COPD), Asthma, Viral Lung Infection and Acute Respiratory Failure
- CM310Phase 35 trials
Keymed Biosciences Co.Ltd · Atopic Dermatitis, Moderate to Severe Asthma, Chronic Obstructive Pulmonary Disease
- Inhaled TreprostinilLIQ861 Inhaled Treprostinil, Inhaled prostacyclinPhase 35 trials
United Therapeutics · Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Progressive Pulmonary Fibrosis
Largest recruiting Phase 3 trials
- A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06283966 · 5,250 participants (planned) · Start Feb 21, 2024 · Primary completion Dec 3, 2027
Drug: BGF MDI 320/14.4/9.6 μg; GFF MDI 14.4/9.6 μg · For: COPD (Chronic Obstructive Pulmonary Disease)
Sites: Athens, Alabama; Cullman, Alabama; Fairhope, Alabama · 922 sites in all
Merck Sharp & Dohme LLCMerck & Co. (MRK)
NCT07874815 · 2,136 participants (planned) · Start Nov 2, 2026 · Primary completion Apr 29, 2029
Drug: Ensifentrine; Standard of Care (SOC) · For: Pulmonary Disease, Chronic Obstructive
Sites: Hialeah Gardens, Florida; Loxahatchee Groves, Florida; Valparaiso, Indiana · 7 sites in all
- The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With BronchiectasisPivotal-lookingRecruiting
Boehringer IngelheimBoehringer Ingelheim
NCT06872892 · 1,755 participants (planned) · Start Jun 9, 2025 · Primary completion Jun 15, 2027
Drug: BI 1291583; Placebo matching BI 1291583 · For: Bronchiectasis
Sites: Birmingham, Alabama; Tucson, Arizona; Newport Beach, California · 474 sites in all
PfizerPfizer (PFE)
NCT07839884 · 1,360 participants (planned) · Start Oct 14, 2026 · Primary completion Apr 21, 2034
Drug: Tilrekimig · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: San Diego, California; Winston-Salem, North Carolina; DuBois, Pennsylvania
- eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 InflammationPivotal-lookingRecruiting
GlaxoSmithKlineGSK (GSK)
NCT07177339 · 1,196 participants (planned) · Start Oct 20, 2025 · Primary completion Apr 2, 2029
Drug: Depemokimab; Placebo · For: Pulmonary Disease, Chronic Obstructive
Sites: Sheffield, Alabama; Tucson, Arizona; Escondido, California · 293 sites in all
- A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary DiseasePivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07363694 · 1,156 participants (planned) · Start Feb 11, 2026 · Primary completion Oct 24, 2030
Drug: PF-07275315 dose 1; PF-07275315-dose 2 and 2 more · For: Moderate to Severe Chronic Obstructive Pulmonary Disease
Sites: Birmingham, Alabama; Dothan, Alabama; Mobile, Alabama · 189 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07772921 · 1,100 participants (planned) · Start Aug 20, 2026 · Primary completion Jun 1, 2029
Drug: tilrekimig · For: Asthma
Sites: Bakersfield, California; Miami, Florida; White Marsh, Maryland · 16 sites in all
- Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone in Adults With Idiopathic Pulmonary Fibrosis (IPF)Pivotal-lookingRecruiting
PureTechIndustry
NCT07284602 · 1,100 participants (planned) · Start Jun 26, 2026 · Primary completion Nov 2029
Drug: Deupirfenidone; Pirfenidone (PFD) · For: Idiopathic Pulmonary Fibrosis (IPF)
Sites: Palm Spring, California; Redding, California; Hialeah, Florida · 18 sites in all
- A Study to Learn About the Study Medicine Called Tilrekimig ( PF-07275315) in People With Severe AsthmaPivotal-lookingRecruiting
PfizerPfizer (PFE)
NCT07869043 · 1,100 participants (planned) · Start Sep 30, 2026 · Primary completion Jun 7, 2029
Drug: tilrekimig · For: Asthma
Sites: River Forest, Illinois; Hannibal, Missouri; The Bronx, New York · 12 sites in all
- A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)Pivotal-lookingRecruiting
AstraZenecaAstraZeneca (AZN)
NCT06878261 · 990 participants (planned) · Start Mar 25, 2025 · Primary completion Mar 13, 2029
Drug: Tezepelumab · For: Chronic Obstructive Pulmonary Disease (COPD)
Sites: Birmingham, Alabama; Cullman, Alabama; Phoenix, Arizona · 284 sites in all
More: Respiratory news · literature
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.